Biogen Idec Undercuts Gilenya With $55,000 Yearly Price For Tecfidera
Executive Summary
The company expects dimethyl fumarate’s strong efficacy and favorable safety and tolerability profile to be an advantage against other oral multiple sclerosis drugs.
You may also be interested in...
Tweet, Tweet, Tweet: Pharma Finding Its Niche?
The industry has been slow to adopt new technologies in the highly regulated pharma world, but both big and small biopharmas alike are beginning to find their comfort zone with limited-character media like Twitter.
NICE’s Tecfidera Restrictions In MS Leave It Fighting For U.K. Market Share
Biogen Idec get nod after providing more data, but restrictions imposed mean Tecfidera is unlikely to leap ahead of a packed field.
Teva’s More Convenient Copaxone Puts Payors In A Bind
Teva Pharmaceutical’s recent launch of a more convenient formulation of its soon-to-be-generic multiple sclerosis blockbuster Copaxone puts payors in a quandary. They must choose whether to position it favorably on formularies, similar to the flexible standing that the original daily injection often enjoys, or restrict access to it in a way that has teeth.